Fulcrum Therapeutics price target lowered to $12 from $14 at Oppenheimer

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Fulcrum Therapeutics (FULC) to $12 from $14 and keeps an Outperform rating on the shares. The firm updated the company’s model post the Q1 report and believes its cash position of $226.6M can sustain operations into 2027. The PIONEER readout remains on track and will likely occur in early July, the analyst tells investors in a research note. Opco says it gets more confident in the readout every time it speaks with management.